Medtronic plc develops and manufactures therapeutic medical devices and healthcare technology for chronic diseases and procedural care. Its news commonly covers regulatory clearances and CE marks, product launches, clinical data, acquisitions, and financial results across cardiovascular, cardiac rhythm management, cranial and spinal technologies, surgical navigation, robotics, and ablation systems.
Recent company updates include the Stealth AXiS™ surgical system for planning, navigation, and robotics; the Affera™ mapping and ablation system with Sphere-9™ and Sphere-360™ catheters; the OmniaSecure™ defibrillation lead; and the completed CathWorks acquisition, including the FFRangio® System for coronary artery disease assessment.
Medtronic (NYSE: MDT) will report third-quarter fiscal 2026 results on Tuesday, February 17, 2026, covering the quarter ended January 23, 2026.
A news release with summary financial information will be issued at ~5:45 a.m. Central Standard Time, followed by a video webcast at 7:00 a.m. CST. Replay and transcript will be posted within 24 hours.
Medtronic (NYSE:MDT) announced its intent to acquire CathWorks for up to $585 million, exercising an option tied to a 2022 strategic partnership. The acquisition aims to expand Medtronic's interventional cardiology portfolio by integrating the CathWorks FFRangio® System, an AI-driven angiography-derived coronary physiology platform.
Deal is subject to United States FTC clearance, expected by the end of Medtronic's fiscal 2026; Medtronic says the transaction is immaterial to FY2027 EPS and neutral to accretive thereafter.
Medtronic (NYSE: MDT) announced three U.S. milestones on Feb 2, 2026: Medicare access for the MiniMed 780G system paired with Abbott's Instinct sensor, FDA clearance to use ultra rapid-acting insulins (Fiasp and Lyumjev) with the 780G, and FDA clearance of the 780G with Instinct for insulin-requiring type 2 diabetes.
These actions expand sensor and insulin options, enable interoperable automated glycemic control for type 2 users, and aim to broaden access and personalization for people using automated insulin delivery.
Medtronic (NYSE:MDT) announced two milestones for the Affera Sphere-360 pulsed field ablation (PFA) catheter: CE Mark in Europe and completion of first cases in the U.S. Horizon 360 IDE pivotal trial on Jan 23, 2026. The Sphere-360 is a rotation-free, all-in-one mapping and single-shot PFA catheter that adapts to pulmonary vein anatomy, provides real-time local impedance, and integrates with the Affera mapping and ablation system. A prospective European single-arm study presented one-year data showing efficacy, safety, and durability that supported CE Mark. The Horizon 360 IDE will evaluate safety and effectiveness for treating paroxysmal atrial fibrillation in U.S. centers.
Medtronic (NYSE: MDT) announced FDA 510(k) clearance of the MiniMed Go™ app and Smart MDI system on January 12, 2026. The system links the InPen smart insulin pen with Abbott's Instinct sensor to provide real-time glucose data, dose calculations, missed-dose alerts, and CareLink reporting. Cleared for insulin-requiring type 1 and type 2 diabetes ages 7+, and ages 2–6 under caregiver supervision. Commercial launch in the U.S. is expected in spring 2026. Compatibility of Simplera sensor remains under FDA review.
Medtronic (MDT) announced a real-world retrospective analysis (CareLink data, Jan 2, 2020–Mar 31, 2025) showing MiniMed 780G users achieved ADA-recommended time-in-range (TIR) goals even on days when mealtime boluses were missed.
Key results: 76.3% TIR on missed-bolus days with recommended optimal settings (100 mg/dL target; 2-hour active insulin time) vs 69.3% TIR for other settings; mean sensor glucose 149 mg/dL vs 160 mg/dL; GMI 6.9% vs 7.1%; >61% met all three ADA targets vs 36.6%.
Study used N=369,467 users (No Bolus cohort N=54,553); deliberate no-bolus is off-label and not recommended.
Medtronic (NYSE: MDT) announced that Chairman and CEO Geoff Martha will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 starting at 10:30 a.m. PST (12:30 p.m. CST). Martha will deliver a formal presentation and take questions, followed by a Q&A session with EVP and CFO Thierry Piéton.
A live webcast and an archive will be available the same day via the Events link on the company's investor relations website.
Medtronic (NYSE: MDT) announced that its Diabetes business, to be named MiniMed, filed a registration statement on Form S-1 with the U.S. SEC on Dec. 19, 2025 for a proposed initial public offering of newly issued common stock.
MiniMed said it intends to list on the Nasdaq Global Select Market under the symbol MMED, prefers a path of an IPO followed by a split-off, and expects the offering to commence after SEC review and subject to market conditions. The number of shares and price range are not yet determined. Securities may not be sold until the registration becomes effective.
Goldman Sachs, BofA Securities, Citigroup and Morgan Stanley are the active bookrunners; several banks will act as joint bookrunning managers and co-managers.
Medtronic (NYSE: MDT) announced a $0.71 per share cash dividend for Q3 of fiscal 2026. The board approved the dividend on December 4, 2025, payable on January 16, 2026 to shareholders of record at the close of business on December 26, 2025.
This declaration is consistent with the company's May 2025 dividend increase and continues Medtronic's track record as a S&P 500 Dividend Aristocrat, having raised its annual dividend for 48 consecutive years.
Medtronic (NYSE: MDT) announced FDA clearance of the Hugo™ robotic-assisted surgery (RAS) system for use in minimally invasive urologic procedures including prostatectomy, nephrectomy, and cystectomy.
The release notes the Expand URO IDE study—described as the largest US multi-port robotic urology trial—met primary safety and effectiveness endpoints, and estimates those urologic procedures total about 230,000 surgeries per year in the U.S. Medtronic plans a purposeful U.S. launch with broader specialty indications expected later.